PHILADELPHIA--(BUSINESS WIRE)--Context Therapeutics, LLC, a clinical-stage biopharmaceutical company focused on hormonally-driven cancers, announced that Martin Lehr, Co-founder and CEO of Context Therapeutics, is a semifinalist for Ernst & Young’s (EY) 2018 Entrepreneur of the Year for the Greater Philadelphia region.
Martin was selected as a semifinalist by an independent panel of judges that includes previous award winners, leading CEOs, private equity and venture capital investors, and other regional business luminaries. The EY Philadelphia Region Award winners will be announced at a gala event to be held on June 14, 2018 in Philadelphia.
“It is a privilege and honor to receive this recognition from EY that acknowledges the growth of Context Therapeutics,” said Lehr. “This award reflects the entrepreneurial drive of every Context Therapeutics team member and our tireless pursuit of developing and delivering novel therapeutics to breast, prostate, and ovarian cancer patients.”
Martin is a life-long entrepreneur and tireless advocate for the Philadelphia biotech ecosystem. In addition to leading Context Therapeutics, Martin is the Director of Philly BioBreak, the biopharmaceutical executive peer networking group aimed at fostering a thriving biotech community in the Greater Philadelphia region. Martin also serves on numerous Philadelphia Board and Advisory committees including Integral Molecular, an antibody discovery company, the Vagelos Life Science Management Program at the University of Pennsylvania, and the Science Center’s QED Program.
For more than 30 years, the Entrepreneur of the Year program has recognized entrepreneurs who demonstrate excellence and extraordinary success in areas such as financial performance, innovation, and commitment to their businesses and communities. It has identified game-changing business leaders and celebrated American ingenuity. Prior winners from the Philadelphia Region include Neal Walker from Aclaris Therapeutics, Jeffrey Marrazzo from Spark Therapeutics, and Joseph Kim from Inovio Pharmaceuticals.
For more information about the 2018 EY Entrepreneur of the Year for the Greater Philadelphia region awards, visit, https://go.ey.com/2JnnASx.
About Context Therapeutic
Context Therapeutics, LLC, is a clinical-stage biopharmaceutical company dedicated to creating new medicines to treat hormone-responsive cancers. Context’s lead program is Apristor (Onapristone XR), an investigational Phase 2 drug that is being developed for progesterone receptor positive (PR+) metastatic breast and ovarian cancers. In addition, Context is advancing CTX-030916, a potential best-in-class oral antiprogestin for the treatment of uterine fibroids and endometriosis, and a discovery-stage program targeting Sigma1.
Context is based in Philadelphia, PA. For more information on Context, please visit www.contexttherapeutics.com.